HLA-DQA1 and UNC119 |
major histocompatibility complex, class II, DQ alpha 1 |
unc-119 homolog (C. elegans) |
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
|
|
|
|
|
HLA-DQA1 and LRIF1 |
major histocompatibility complex, class II, DQ alpha 1 |
ligand dependent nuclear receptor interacting factor 1 |
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
|
|
|
|
|
HLA-DQA1 and TLE1 |
major histocompatibility complex, class II, DQ alpha 1 |
transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) |
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by NOTCH1 in Cancer
- truncations of AMER1 destabilize the destruction complex
- FBXW7 Mutants and NOTCH1 in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- NOTCH1 Intracellular Domain Regulates Transcription
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by WNT in cancer
|
|
|
|
|
HLA-DQA1 and SH3GL2 |
major histocompatibility complex, class II, DQ alpha 1 |
SH3-domain GRB2-like 2 |
- Generation of second messenger molecules
- Downstream TCR signaling
- Costimulation by the CD28 family
- Translocation of ZAP-70 to Immunological synapse
- Interferon Signaling
- Cytokine Signaling in Immune system
- Interferon gamma signaling
- TCR signaling
- MHC class II antigen presentation
- PD-1 signaling
- Phosphorylation of CD3 and TCR zeta chains
- Adaptive Immune System
|
- Retrograde neurotrophin signalling
- EGFR downregulation
- Signalling by NGF
- Axon guidance
- Golgi Associated Vesicle Biogenesis
- L1CAM interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by EGFRvIII in Cancer
- Recycling pathway of L1
- Clathrin derived vesicle budding
- Lysosome Vesicle Biogenesis
- Signaling by EGFR
- MHC class II antigen presentation
- Signaling by EGFR in Cancer
- trans-Golgi Network Vesicle Budding
- Adaptive Immune System
|
|
|
|
|
LMO7 and MDM2 |
LIM domain 7 |
MDM2 proto-oncogene, E3 ubiquitin protein ligase |
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- Stabilization of p53
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Transmission across Chemical Synapses
- PIP3 activates AKT signaling
- Oncogene Induced Senescence
- p53-Dependent G1 DNA Damage Response
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- G1/S DNA Damage Checkpoints
- Innate Immune System
- Signalling by NGF
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Trafficking of AMPA receptors
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- Oxidative Stress Induced Senescence
- Cell Cycle Checkpoints
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
|
|
- Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
- Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
|
|
|
MDM2 and RNF10 |
MDM2 proto-oncogene, E3 ubiquitin protein ligase |
ring finger protein 10 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- Stabilization of p53
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Transmission across Chemical Synapses
- PIP3 activates AKT signaling
- Oncogene Induced Senescence
- p53-Dependent G1 DNA Damage Response
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- G1/S DNA Damage Checkpoints
- Innate Immune System
- Signalling by NGF
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Trafficking of AMPA receptors
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- Oxidative Stress Induced Senescence
- Cell Cycle Checkpoints
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
|
|
- Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
- Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
|
|
|
|
MDM2 and RBM38 |
MDM2 proto-oncogene, E3 ubiquitin protein ligase |
RNA binding motif protein 38 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- Stabilization of p53
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Transmission across Chemical Synapses
- PIP3 activates AKT signaling
- Oncogene Induced Senescence
- p53-Dependent G1 DNA Damage Response
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- G1/S DNA Damage Checkpoints
- Innate Immune System
- Signalling by NGF
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Trafficking of AMPA receptors
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- Oxidative Stress Induced Senescence
- Cell Cycle Checkpoints
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
|
|
- Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
- Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
|
|
|
|
TGFB3 and TGFBR3 |
transforming growth factor, beta 3 |
transforming growth factor, beta receptor III |
- Molecules associated with elastic fibres
- Elastic fibre formation
- Response to elevated platelet cytosolic Ca2+
- ECM proteoglycans
- Platelet degranulation
- Platelet activation, signaling and aggregation
|
|
|
|
|
|
KCNJ2 and KCNJ11 |
potassium channel, inwardly rectifying subfamily J, member 2 |
potassium channel, inwardly rectifying subfamily J, member 11 |
- GABA B receptor activation
- Inwardly rectifying K+ channels
- GABA receptor activation
- Activation of G protein gated Potassium channels
- Classical Kir channels
- Activation of GABAB receptors
- Potassium Channels
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- G protein gated Potassium channels
- Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
- Transmission across Chemical Synapses
|
- Inwardly rectifying K+ channels
- Integration of energy metabolism
- ATP sensitive Potassium channels
- Regulation of insulin secretion
- Potassium Channels
|
|
- Glimepiride
- Ibutilide
- Verapamil
- Levosimendan
- Glyburide
- Diazoxide
- Thiamylal
|
|
|
MEN1 and MYH9 |
multiple endocrine neoplasia I |
myosin, heavy chain 9, non-muscle |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Signaling by Wnt
- TGFBR1 LBD Mutants in Cancer
- deactivation of the beta-catenin transactivating complex
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- formation of the beta-catenin:TCF transactivating complex
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- TCF dependent signaling in response to WNT
- Signaling by WNT in cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
- EPHA-mediated growth cone collapse
- Axon guidance
- Semaphorin interactions
- EPH-Ephrin signaling
- Sema4D in semaphorin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- Regulation of actin dynamics for phagocytic cup formation
- Sema4D induced cell migration and growth-cone collapse
- Innate Immune System
|
|
|
|
|
RUNX1 and FOXP3 |
runt-related transcription factor 1 |
forkhead box P3 |
|
|
|
|
|
|
CTLA4 and PTPN11 |
cytotoxic T-lymphocyte-associated protein 4 |
protein tyrosine phosphatase, non-receptor type 11 |
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
- Signaling by FGFR in disease
- Netrin mediated repulsion signals
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Toll Like Receptor TLR1:TLR2 Cascade
- PI3K/AKT activation
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Prolactin receptor signaling
- SHC-mediated signalling
- PI3K Cascade
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- Spry regulation of FGF signaling
- Constitutive PI3K/AKT Signaling in Cancer
- Platelet sensitization by LDL
- Signaling by VEGF
- Signalling to RAS
- Toll Like Receptor 3 (TLR3) Cascade
- Downstream signal transduction
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Frs2-mediated activation
- Adaptive Immune System
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- GRB2 events in ERBB2 signaling
- VEGFR2 mediated cell proliferation
- PI3K events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- Netrin-1 signaling
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- Interferon Signaling
- CTLA4 inhibitory signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Tie2 Signaling
- PECAM1 interactions
- Signaling by FGFR
- ARMS-mediated activation
- Nuclear signaling by ERBB4
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PD-1 signaling
- PI3K Cascade
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- DAP12 signaling
- PI-3K cascade
- Toll Like Receptor 9 (TLR9) Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- Regulation of IFNA signaling
- GAB1 signalosome
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Signal regulatory protein (SIRP) family interactions
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Platelet homeostasis
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- Costimulation by the CD28 family
- ERK activation
- PIP3 activates AKT signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Interferon alpha/beta signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- MyD88-independent cascade
- Cell surface interactions at the vascular wall
- ERK2 activation
- SHC1 events in EGFR signaling
- IRS-mediated signalling
- FRS2-mediated cascade
- ERK2 activation
- Regulation of IFNG signaling
|
|
|
|
|
ERBB3 and FLNA |
erb-b2 receptor tyrosine kinase 3 |
filamin A, alpha |
|
- Cell junction organization
- GP1b-IX-V activation signalling
- Response to elevated platelet cytosolic Ca2+
- Platelet degranulation
- Platelet activation, signaling and aggregation
- Cell-extracellular matrix interactions
|
|
|
|
|
ERBB3 and FGFR1 |
erb-b2 receptor tyrosine kinase 3 |
fibroblast growth factor receptor 1 |
|
- Signaling by FGFR in disease
- Signaling by activated point mutants of FGFR1
- Signaling by FGFR1 mutants
- Signaling by FGFR mutants
|
|
|
|
|
KCNQ1 and KCNE2 |
potassium channel, voltage gated KQT-like subfamily Q, member 1 |
potassium channel, voltage gated subfamily E regulatory beta subunit 2 |
- Potassium Channels
- Voltage gated Potassium channels
|
|
|
|
|
|
PTPN11 and RET |
protein tyrosine phosphatase, non-receptor type 11 |
ret proto-oncogene |
- Signaling by FGFR in disease
- Netrin mediated repulsion signals
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Toll Like Receptor TLR1:TLR2 Cascade
- PI3K/AKT activation
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Prolactin receptor signaling
- SHC-mediated signalling
- PI3K Cascade
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- Spry regulation of FGF signaling
- Constitutive PI3K/AKT Signaling in Cancer
- Platelet sensitization by LDL
- Signaling by VEGF
- Signalling to RAS
- Toll Like Receptor 3 (TLR3) Cascade
- Downstream signal transduction
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Frs2-mediated activation
- Adaptive Immune System
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- GRB2 events in ERBB2 signaling
- VEGFR2 mediated cell proliferation
- PI3K events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- Netrin-1 signaling
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- Interferon Signaling
- CTLA4 inhibitory signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Tie2 Signaling
- PECAM1 interactions
- Signaling by FGFR
- ARMS-mediated activation
- Nuclear signaling by ERBB4
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PD-1 signaling
- PI3K Cascade
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- DAP12 signaling
- PI-3K cascade
- Toll Like Receptor 9 (TLR9) Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- Regulation of IFNA signaling
- GAB1 signalosome
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Signal regulatory protein (SIRP) family interactions
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Platelet homeostasis
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- Costimulation by the CD28 family
- ERK activation
- PIP3 activates AKT signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Interferon alpha/beta signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- MyD88-independent cascade
- Cell surface interactions at the vascular wall
- ERK2 activation
- SHC1 events in EGFR signaling
- IRS-mediated signalling
- FRS2-mediated cascade
- ERK2 activation
- Regulation of IFNG signaling
|
|
|
|
|
|
ANK1 and SLC4A1 |
ankyrin 1, erythrocytic |
solute carrier family 4 (anion exchanger), member 1 (Diego blood group) |
- Interaction between L1 and Ankyrins
- CHL1 interactions
- Axon guidance
- Neurofascin interactions
- NrCAM interactions
- L1CAM interactions
|
- O2/CO2 exchange in erythrocytes
- Erythrocytes take up carbon dioxide and release oxygen
- Transport of inorganic cations/anions and amino acids/oligopeptides
- Erythrocytes take up oxygen and release carbon dioxide
- SLC-mediated transmembrane transport
- Bicarbonate transporters
|
|
|
|
|
AR and TCF4 |
androgen receptor |
transcription factor 4 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- CDO in myogenesis
- Myogenesis
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and TBP |
androgen receptor |
TATA box binding protein |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- RNA Polymerase II Promoter Escape
- RNA Polymerase III Transcription Initiation From Type 3 Promoter
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase I Chain Elongation
- RNA Polymerase II Transcription
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- RNA Polymerase I Transcription Initiation
- RNA Polymerase I Promoter Clearance
- HIV Infection
- RNA Polymerase II Pre-transcription Events
- HIV Life Cycle
- HIV Transcription Initiation
- NoRC negatively regulates rRNA expression
- RNA Polymerase II HIV Promoter Escape
- RNA Polymerase III Transcription Initiation
- RNA Polymerase III Transcription
- RNA Polymerase III Transcription Initiation From Type 1 Promoter
- RNA Polymerase I Transcription
- RNA Polymerase I Transcription Termination
- RNA Polymerase I Promoter Escape
- Epigenetic regulation of gene expression
- Negative epigenetic regulation of rRNA expression
- Late Phase of HIV Life Cycle
- RNA Polymerase III Transcription Initiation From Type 2 Promoter
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- RNA Polymerase III Abortive And Retractive Initiation
- RNA Polymerase II Transcription Initiation
- SIRT1 negatively regulates rRNA Expression
- Transcription of the HIV genome
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
CTLA4 and JAK2 |
cytotoxic T-lymphocyte-associated protein 4 |
Janus kinase 2 |
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Prolactin receptor signaling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- RMTs methylate histone arginines
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Nuclear signaling by ERBB4
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- G-protein beta:gamma signalling
- Chromatin organization
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Factors involved in megakaryocyte development and platelet production
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Chromatin modifying enzymes
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Growth hormone receptor signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
|
|
|
|